文献速递神经免疫

多发性硬化患者乳腺癌生存率:匹配队列研究

Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
PubMed 文献 · Neurology · 2021-05-19

该研究基于加拿大马尼托巴省和安大略省的人群行政数据,采用回顾性匹配队列设计,比较多发性硬化(MS)女性与无MS女性在乳腺癌诊断后的生存情况。共纳入779例MS患者和3,116例对照。调整协变量后,MS与全因死亡风险增加28%相关(HR 1.28;95%CI 1.08-1.53),但未改变乳腺癌特异性生存(HR 0.98;95%CI 0.65-1.46)。

要点

  • MS女性乳腺癌诊断后全因死亡风险较无MS女性高28%。
  • MS未与乳腺癌特异性生存改变相关。
  • 未来需在其他人群中验证并识别与不良预后相关的MS特异因素。

核心结论

  • MS女性乳腺癌诊断后全因生存低于无MS女性,但乳腺癌特异性生存无差异。

研究设计与样本

  • 回顾性匹配队列研究,基于加拿大马尼托巴省和安大略省人群行政数据,纳入779例MS患者和3,116例匹配对照。
  • 按出生年份、癌症诊断年份和地区为每例MS患者匹配4例无MS乳腺癌对照。
  • 采用Cox比例风险回归比较全因生存,采用多变量病因特异性风险模型比较癌症特异性生存,并用荟萃分析合并两省结果。

主要发现

  • 调整年龄、诊断时期、收入五分位、地区和Elixhauser合并症评分后,MS与全因死亡风险增加28%相关(HR 1.28;95%CI 1.08-1.53)。
  • MS与乳腺癌特异性生存改变无关(HR 0.98;95%CI 0.65-1.46)。
  • 有分期数据的患者中70.0%(1,976/2,822)为I或II期乳腺癌,诊断时平均年龄57.8岁(SD 10.7)。

临床怎么用

  • 对合并MS的乳腺癌女性应关注总体生存和合并症管理,而非仅关注乳腺癌特异性预后。

局限性

  • 结论需在其他人群中验证,且需识别与不良预后相关的MS特异因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the hypotheses that overall survival and cancer-specific survival after breast cancer diagnosis would be lower in persons with multiple sclerosis (MS) as compared to persons without MS using a retrospective matched cohort design. METHODS: We applied a validated case definition to population-based administrative data in Manitoba and Ontario, Canada, to identify women with MS. We linked the MS cohorts to cancer registries to identify women with breast cancer. Then we selected 4 breast cancer controls without MS matched on birth year, cancer diagnosis year, and region. We compared all-cause survival between cohorts using Cox proportional hazards regression adjusting for age at cancer diagnosis, cancer diagnosis period, income quintile, region, and Elixhauser comorbidity score. We compared cancer-specific survival between cohorts using a multivariable cause-specific hazards model. We pooled findings between provinces using meta-analysis. RESULTS: We included 779 patients with MS and 3,116 controls with breast cancer. Most patients with stage data (1,976/2,822 [70.0%]) were diagnosed with stage I or II breast cancer and the mean (SD) age at diagnosis was 57.8 (10.7) years. After adjustment for covariates, MS was associated with a 28% increased hazard for all-cause mortality (hazard ratio [HR] 1.28; 95% confidence interval [CI] 1.08-1.53), but was not associated with altered cancer-specific survival (HR 0.98; 95% CI 0.65-1.46). CONCLUSION: Women with MS have lower all-cause survival after breast cancer diagnosis than women without MS. Future studies should confirm these findings in other populations and identify MS-specific factors associated with worse prognosis.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Marrie RA, Maxwell C, Mahar A, et al. Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study. Neurology. 2021. PMID: 34011575. doi:10.1212/WNL.0000000000012127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。